Regeneron Pharmaceuticals R&D decreased by 5.1% to $1.54B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.3%, from $1.33B to $1.54B. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 19.1% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $714.20M | $665.40M | $785.60M | $843.80M | $794.30M | $911.30M | $1.04B | $1.10B | $1.09B | $1.08B | $1.18B | $1.25B | $1.20B | $1.27B | $1.41B | $1.33B | $1.42B | $1.48B | $1.63B | $1.54B |
| QoQ Change | — | -6.8% | +18.1% | +7.4% | -5.9% | +14.7% | +14.5% | +5.6% | -1.4% | -0.9% | +9.5% | +6.0% | -3.9% | +6.0% | +11.1% | -6.0% | +7.1% | +3.7% | +10.2% | -5.1% |
| YoY Change | — | — | — | — | +11.2% | +37.0% | +32.8% | +30.5% | +36.6% | +18.0% | +12.9% | +13.4% | +10.6% | +18.2% | +20.0% | +6.3% | +18.5% | +16.0% | +15.2% | +16.3% |
Range$665.40M – $1.63B
CAGR+17.6%
Avg YoY Growth+19.6%
Median YoY Growth+17.1%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $1.33B | $1.42B | $1.48B | $1.63B | $1.54B |
| Total | $1.33B | $1.42B | $1.48B | $1.63B | $1.54B |
R&D at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's r&d?
- Regeneron Pharmaceuticals (REGN) reported r&d of $1.54B in Q1 2026.
- How has Regeneron Pharmaceuticals's r&d changed year-over-year?
- Regeneron Pharmaceuticals's r&d increased by 16.3% year-over-year, from $1.33B to $1.54B.
- What is the long-term trend for Regeneron Pharmaceuticals's r&d?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's r&d has grown at a 19.1% compound annual growth rate (CAGR), from $2.91B to $5.85B.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.